T. Rowe Price Investment Management, Inc. 13D and 13G filings for Ionis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:18 pm Sale | 2025-09-30 | 13G | Ionis Pharmaceuticals, Inc. IONS | T. Rowe Price Investment Management, Inc. | 13,157,114 8.300% | -2,694,749 (-17.00%) | Filing |
| 2025-02-07 11:55 am Purchase | 2025-01-31 | 13G | Ionis Pharmaceuticals, Inc. IONS | T. Rowe Price Investment Management, Inc. | 15,851,863 10.000% | 1,683,747 (+11.88%) | Filing |
| 2024-11-14 1:28 pm Purchase | 2024-09-30 | 13G | Ionis Pharmaceuticals, Inc. IONS | T. Rowe Price Investment Management, Inc. | 14,168,116 9.000% | 966,663 (+7.32%) | Filing |
| 2024-02-14 10:04 am Purchase | 2023-12-31 | 13G | Ionis Pharmaceuticals, Inc. IONS | T. Rowe Price Investment Management, Inc. | 13,201,453 9.200% | 1,523,194 (+13.04%) | Filing |
| 2023-02-14 12:40 pm Purchase | 2022-12-31 | 13G | Ionis Pharmaceuticals, Inc. IONS | T. Rowe Price Investment Management, Inc. | 11,678,259 8.200% | 11,678,259 (New Position) | Filing |